LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.

November 12, 2024908 Devices Inc. misses on earnings expectations. Reported EPS is $-0.84495 EPS, expectations were $-0.28.

Government AI adoption is expected to rapidly accelerate in 2025, with 84% of government decision makers saying in a recent global study, Your Journey to a GenAI Future: A Strategic Path to Success ...

In 2021, the cost of a completed drug development cycle was estimated at $2.6 billion. Phase 1: Discovery and Preclinical ...

We’re making a lot of progress, but we're not yet solving the climate problem,” said David Victor, professor of public policy ...

In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.

Now I’ll discuss the anticipated U.S. launch of 512, for which Phase III pivotal studies were presented at ... and I would say that you expect in a 10-year cycle to see, especially when you’ve got the ...

Repairify, the global leader in remote diagnostics, calibrations, programming, and automotive intelligence for the collision and mechanical repair industries, announced today a new integration between ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative ...